Silence Therapeutics PLC experienced a pronounced intraday rally, climbing +16.2% in mid-day trading after Cantor Fitzgerald initiated coverage with an Overweight rating. In the firm's published initiation note, analyst Prakhar Agrawal stated that the shares appear materially undervalued when measured against the potential of the company’s lead asset, divesiran.
Cantor Fitzgerald’s coverage centers on divesiran’s ongoing Phase 2 SANRECO trial, which targets polycythemia vera, a rare blood disorder. The trial has a near-term binary event on the calendar: topline data are expected in August 2026. In his initiation, Agrawal assigned a 75% probability of success to that readout.
The new initiation amplified institutional attention on Silence, adding to an existing base of positive analyst views. Prior to Cantor Fitzgerald’s note, the company already carried Buy-equivalent ratings from H.C. Wainwright and Chardan, creating a convergent analyst view ahead of the pivotal Phase 2 results.
Investor enthusiasm has also been reinforced by recently presented follow-up data from the Phase 1 SANRECO cohort. Those results, shown at the EHA 2026 congress in June, indicated a sharp reduction in phlebotomy rates among treated polycythemia vera patients and reported a favorable safety profile for divesiran. Together, the data and the new analyst endorsement appear to have strengthened conviction in the drug’s clinical and commercial prospects.
Market conditions provided only a modestly supportive backdrop. The S&P 500 rose +0.4%, the Dow Jones gained +0.8%, and the NASDAQ climbed +0.3% on the same day. Those broader moves were relatively small and insufficient to account for Silence Therapeutics’ outsized session gain, underscoring that today’s price action was largely company-specific.
As investors positioned for the upcoming Phase 2 catalyst, the stock traded to a fresh 52-week high intraday of $8.80. The combination of a high-profile analyst start, a well-timed endorsement ahead of a near-term data event, and existing favorable coverage created the conditions for a rapid re-rating of the shares.
Looking ahead, market participants will be monitoring developments tied to the SANRECO trial and any additional analyst commentary or institutional interest that may follow Cantor Fitzgerald’s initiation. For now, the stock’s jump reflects elevated investor confidence in divesiran’s pathway toward potential regulatory and commercial milestones.
Summary
Cantor Fitzgerald initiated coverage of Silence Therapeutics with an Overweight rating, highlighting divesiran and assigning a 75% chance of success for the Phase 2 SANRECO topline expected in August 2026. The initiation, together with favorable Phase 1 follow-up data presented at EHA 2026 and existing Buy-equivalent ratings from other brokers, triggered a company-specific stock rally that pushed shares to a new 52-week intraday high.
Key points
- Cantor Fitzgerald launched coverage with an Overweight rating and a 75% probability of success for the Phase 2 SANRECO topline.
- Encouraging Phase 1 follow-up data presented at EHA 2026 showed reduced phlebotomy rates and a favorable safety profile for divesiran.
- Broader market gains were modest, indicating the stock’s surge was driven primarily by company-specific developments in the biotech sector.
Risks and uncertainties
- The August 2026 Phase 2 SANRECO topline is a binary event; its outcome will materially affect investor sentiment and the stock’s trajectory.
- Analyst probabilities and ratings reflect opinion rather than guaranteed outcomes; the 75% probability assigned to success is an analyst estimate.
- While Phase 1 follow-up data were encouraging, Phase 2 results remain pending and will be the primary determinant of divesiran’s near-term clinical outlook.